Lung Clinical Trials
Delivering quality care through clinical trials
Available clinical trials are below. Click the + sign to expand and review details about their purpose, eligibility criteria, and contact information for study staff. For some studies, you will find a link to ClinicalTrials.gov, where you can explore more information about each study.
Veracyte - DHF 009-053P - (NIGHTINGALE)
Study Phase: Observational - Screening
Condition(s): Pulmonary nodules
Clinical Utility of Management of Patients with CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier - with Familiarization
ClinicalTrials.gov NCT ID: NCT06426628
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
AstraZeneca - D926TC00001 - (TROPION-Lung 12)
Study Phase: Phase III - Drug
Condition(s): Stage I non-small cell Lung cancer
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features
ClinicalTrials.gov NCT ID: NCT06564844
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
NRG - NRG-LU007
Study Phase: Phase II/III - Drug
Condition(s): Extensive stage small cell lung cancer
Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
ClinicalTrials.gov NCT ID: NCT04402788
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
Merck V940-009
Study Phase: Phase III - Drug
Condition(s): Stage II - IIIB NSCLC
Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab with or without V940 in Resectable Stages II-IIIB(N2) NSCLC for patients not achieving pCR after receiving Neoadjuvant Pembrolizumab with chemotherapy followed by surgery
ClinicalTrials.gov NCT ID: NCT06623422
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
Merck MK2870-023
Study Phase: Phase III - Drug
Condition(s): Stage IV squamous NSCLC
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab with or without Maintenance MK2870 in the First-line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer
ClinicalTrials.gov NCT ID: NCT06422143
You can view the full clinical description on ClinicalTrials.gov.
View Full Description
To inquire if you're eligible for a clinical trial, contact: (484) 658-5080, or click here to complete a clinical trial inquiry form.
